CBER’s first untitled letter of 2023 dings clinic over unlicensed stem cell products
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesComplianceNorth AmericaRegulatory Intelligence/PolicyRegulatory NewsMichael MezherBiologics/ biosimilars/ vaccinesComplianceNorth AmericaRegulatory Intelligence/Policy